test Browse by Author Names Browse by Titles of Works Browse by Subjects of Works Browse by Issue Dates of Works
       

Advanced Search
Home   
 
Browse   
Communities
& Collections
  
Issue Date   
Author   
Title   
Subject   
 
Sign on to:   
Receive email
updates
  
My Account
authorized users
  
Edit Profile   
 
Help   
About T-Space   

T-Space at The University of Toronto Libraries >
Faculty of Medicine >
Faculty Publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1807/16674

Title: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers
Authors: Narod, SA
Eisen, A
Lubinski, J
Gronwald, J
Moller, P
Lynch, HT
Klijn, J
Kim-Sing, C
Neuhausen, SL
Gilbert, L
Ghadirian, P
Manoukian, S
Rennert, G
Friedman, E
Isaacs, C
Rosen, E
Rosen, B
Daly, M
Sun, P
Department: Dalla Lana School of Public Health
Women's College Research Institute
Keywords: Breast Neoplasms
Estrogen Replacement Therapy
Estrogens
Women's Health
Genes
BRCA1 gene
Postmenopause
Progestins
Risk Assessment
Risk Factors
Hormone Replacement Therapy
Breast Cancer
Issue Date: 1-Oct-2008
Publisher: Journal of the National Cancer Institute
Citation: Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008 Oct 1;100(19):1361-7. Epub 2008 Sep 23. Available from: http://jnci.oxfordjournals.org/cgi/content/full/100/19/1361
Series/Report no.: PMID
18812548
Abstract: BACKGROUND: Hormone therapy (HT) is commonly given to women to alleviate the climacteric symptoms associated with menopause. There is concern that this treatment may increase the risk of breast cancer. The potential association of HT and breast cancer risk is of particular interest to women who carry a mutation in BRCA1 because they face a high lifetime risk of breast cancer and because many of these women take HT after undergoing prophylactic surgical oophorectomy at a young age. METHODS: We conducted a matched case-control study of 472 postmenopausal women with a BRCA1 mutation to examine whether or not the use of HT is associated with subsequent risk of breast cancer. Breast cancer case patients and control subjects were matched with respect to age, age at menopause, and type of menopause (surgical or natural). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated with conditional logistic regression. Statistical tests were two-sided. RESULTS: In this group of BRCA1 mutation carriers, the adjusted OR for breast cancer associated with ever use of HT compared with never use was 0.58 (95% CI = 0.35 to 0.96; P = .03). In analyses by type of HT, an inverse association with breast cancer risk was observed with use of estrogen only (OR = 0.51, 95% CI = 0.27 to 0.98; P = .04); the association with use of estrogen plus progesterone was not statistically significant (OR = 0.66, 95% CI = 0.34 to 1.27; P = .21). CONCLUSION: Among postmenopausal women with a BRCA1 mutation, HT use was not associated with increased risk of breast cancer; indeed, in this population, it was associated with a decreased risk.
URI: http://hdl.handle.net/1807/16674
ISSN: 0027-8874
Appears in Collections:Faculty Publications
Narod, Steven

Files in This Item:

File Description SizeFormat
Hormone_BRCA_Narod.pdf110.29 kBAdobe PDF
View/Open

Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

uoft